Cutaneous T-cell lymphoma and atopy: is there an association?

被引:35
|
作者
Mehrany, K [1 ]
El-Azhary, RA [1 ]
Bouwhuis, SA [1 ]
Pittelkow, MR [1 ]
机构
[1] Mayo Clin, Dept Dermatol, Rochester, MN 55905 USA
关键词
atopic dermatitis; cutaneous T-cell lymphoma; mycosis fungoides; Sezary syndrome;
D O I
10.1111/j.1365-2133.2003.05551.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Case reports have suggested a relationship between atopic diatheses and Sezary syndrome, pre-Sezary syndrome or mycosis fungoides. However, Sezary and pre-Sezary syndromes are rare entities, and this association has never been analysed in greater detail for specific subtypes of cutaneous T-cell lymphoma (CTCL). Objectives To evaluate the prevalence of atopy in subjects with Sezary syndrome, pre-Sezary syndrome or mycosis fungoides, and to compare the rates with the reported prevalence of atopy in the general population. Methods We retrospectively reviewed the records of 157 patients with the diagnosis of Sezary or pre-Sezary syndrome seen between 1965 and 2000, and 102 patients with the diagnosis of mycosis fungoides evaluated from 1994 to 2000 at Mayo Clinic. Results Of 157 subjects with Sezary or pre-Sezary syndrome and 102 subjects with mycosis fungoides, 18 and 12, respectively, were identified as having a history of atopic dermatitis, asthma or allergic rhinitis. The prevalence rates of atopy in Sezary or pre-Sezary syndrome and mycosis fungoides were 11.5% (95% confidence interval 6.9-17.5%) and 11.8% (6.2-19.7%), respectively. Conclusions No significant difference exists in the prevalence of atopy in Sezary or pre-Sezary syndrome compared with that in mycosis fungoides (chi(2)-test, P = 1.00). Furthermore, the rates of atopy in Sezary or pre-Sezary syndrome and mycosis fungoides are not significantly different from the prevalence of atopy in the general population (17-40%). On the basis of these observations, no evidence currently implicates a causal association of CTCL with atopy.
引用
收藏
页码:1013 / 1017
页数:5
相关论文
共 50 条
  • [21] Menus for Managing Patients With Cutaneous T-Cell Lymphoma
    Poligone, Brian
    Heald, Peter
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2012, 31 (01) : 25 - 32
  • [22] Emerging drugs for the treatment of cutaneous T-cell lymphoma
    Cheng, Melissa
    Zain, Jasmine
    Rosen, Steven T.
    Querfeld, Christiane
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (01) : 45 - 54
  • [23] Skin Directed Therapy in Cutaneous T-Cell Lymphoma
    Tarabadkar, Erica S.
    Shinohara, Michi M.
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [24] Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
    Lech-Maranda, Ewa
    Robak, Ewa
    Robak, Tadeusz
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2011, 6 (01) : 70 - 93
  • [25] Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma
    Pelcovits, Ari
    Ollila, Thomas A.
    Olszewski, Adam J.
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 989 - 998
  • [26] Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
    Prince, H. Miles
    Newland, Kate M.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (06): : 625 - 634
  • [27] New and emerging therapies in cutaneous T-cell lymphoma
    Roccuzzo, Gabriele
    Macagno, Nicole
    Giordano, Silvia
    Fava, Paolo
    Quaglino, Pietro
    DERMATOLOGY REPORTS, 2025, 17 (01)
  • [28] CAUSES OF DEATH IN CUTANEOUS T-CELL LYMPHOMA PATIENTS
    Lebas, Eve
    Collins, Patrick
    Somja, Joan
    Nikkels, Arjen
    DERMATOLOGY, 2023, 239 (06) : 860 - 867
  • [29] The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma
    Spaccarelli, Natalie
    Rook, Alain H.
    DERMATOLOGIC CLINICS, 2015, 33 (04) : 731 - +
  • [30] Treatment of cutaneous T-cell lymphoma with extracorporeal photochemotherapy
    Konstantinow, A
    Balda, BR
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 1997, 9 (02) : 111 - 117